Open AccessCpG Oligodeoxynucleotides Adsorbed onto Polylactide-Co-Glycolide Microparticles Improve the Immunogenicity and Protective Activity of the Licensed Anthrax Vaccine
Author(s) -
Hang Xie,
İhsan Gürsel,
Bruce E. Ivins,
Manmohan Singh,
Derek T. O’Hagan,
Jeffrey B. Ulmer,
Dennis M. Klinman
Publication year - 2005
Publication title -
infection and immunity
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.508
H-Index - 220
eISSN - 1070-6313
pISSN - 0019-9567
DOI - 10.1128/iai.73.2.828-833.2005
Subject(s) - anthrax vaccines , immunogenicity , bacillus anthracis , cpg oligodeoxynucleotide , vaccination , antigen , biology , anthrax toxin , immunity , virology , microbiology and biotechnology , cpg site , antibody , immunology , immune system , dna vaccination , recombinant dna , immunization , biochemistry , fusion protein , gene expression , genetics , dna methylation , bacteria , gene
To reduce the biothreat posed by anthrax, efforts are under way to improve the protection afforded by vaccination. This work examines the ability of immunostimulatory CpG oligodeoxynucleotides (ODN) adsorbed onto cationic polylactide-co-glycolide (PLG) microparticles (CpG ODN-PLG) to accelerate and boost the protective immunity elicited by Anthrax Vaccine Adsorbed (AVA, the licensed human anthrax vaccine). The results indicate that coadministering CpG ODN-PLG with AVA induces a stronger and faster immunoglobulin G response against the protective antigen of anthrax than AVA alone. Immunized mice were protected from lethal anthrax challenge within 1 week of vaccination with CpG ODN-PLG plus AVA, with the level of protection correlating with serum immunoglobulin G anti-protective antigen titers.